|
|
Post by Hot Christian Stocks on Mar 11, 2014 8:06:13 GMT -5
$NVLX Nuvilex Appoints CEO and President of Austrianova to Scientific Advisory BoardNuvilex Appoints CEO and President of Austrianova to Scientific Advisory Board Dr. Brian Salmons Indispensable for Development of Cannabis-Based Cancer Treatments SILVER SPRING, Md., March 11, 2014 (GLOBE NEWSWIRE) -- Nuvilex, Inc. (OTCQB:NVLX), an international biotechnology company providing cell and gene therapy solutions for the treatment of deadly diseases, announced today that its subsidiary, Medical Marijuana Sciences, Inc., has appointed Brian Salmons, Ph.D., CEO and President of Nuvilex's partner Austrianova, to its Scientific Advisory Board. Dr. Salmons, together with Professor Dr. Walter H. Günzburg, invented and developed the live-cell encapsulation technology now known as Cell-in-a-Box(TM) which has been licensed by Nuvilex for the development of treatments for cancer and diabetes. It is expected that, given his expertise in this and other aspects of the development of disease treatments, Dr. Salmons will play a pivotal role as Medical Marijuana Sciences goes forward with its cannabis-based cancer treatments. Dr. Brian Salmons received his Ph.D. in London. After research positions in the U.S.A., Switzerland and at the Ludwig Maximilian University in Munich, Germany, Dr. Salmons became the Scientific Director of the European biotech/vaccine company, Bavarian Nordic, and was intricately involved in taking the company to an IPO. Bavarian Nordic was sponsor of the Phase1/2 clinical trial in patients with advanced, inoperable pancreatic cancer that involved the use of the combination of live-cell encapsulation and the anti-cancer prodrug ifosfamide. The results of this trial showed that the combination was safe and efficacious. These results were reported in reputable scientific literature and can be viewed by clicking here (please scroll down and click on blue title opposite "121-131"). In 2002, Dr. Salmons co-founded the biotech company, Austrianova, originally a "spin-off" from the Veterinary Medicine University in Vienna. He was instrumental in obtaining orphan drug status from the European Medicines Agency for its lead cell encapsulation product. In 2007, Dr. Salmons co-founded and became the CEO and President of Austrianova Singapore Pte. Ltd., an independent company established in Singapore to further develop the live-cell encapsulation technology as products for a variety of indications such as various forms of cancer, diabetes, neurodegenerative, cardiovascular and infectious diseases. Dr. Salmons is the author or co-author of over 120 peer-reviewed scientific articles and inventor of 8 patent families. Dr. Mark L. Rabe, Chairman of Medical Marijuana Sciences' Scientific Advisory Board, commented, "Dr. Salmons' acceptance of his appointment as a member of the Medical Marijuana Sciences Scientific Advisory Board is a major coup for Nuvilex. His complete knowledge of the Cell-in-a-Box(TM) encapsulation technology, and its many possible applications, will be invaluable as we strive to develop treatments for the deadliest of all cancers employing Cell-in-a-Box(TM) technology in combination with cannabis-based compounds." www.stockwatch.com/News/Item.aspx?bid=U-z10072083-U%3aNVLX-20140311&symbol=NVLX®ion=U
|
|
|
|
Post by Hot Christian Stocks on Mar 12, 2014 8:16:26 GMT -5
|
|
|
|
Post by Hot Christian Stocks on Mar 13, 2014 7:29:51 GMT -5
|
|
|
|
Post by Hot Christian Stocks on Mar 14, 2014 8:33:15 GMT -5
|
|
|
|
Post by Hot Christian Stocks on Mar 17, 2014 5:53:10 GMT -5
$NVLX New 10Q March 17, 2014 updated SS Common Stock, authorized 1,490,000,000 shares, $0.0001 par value, 602,958,014 and 482,106,348 shares issued and outstanding, respectively www.otcmarkets.com/edgar/GetFilingHtml?FilingID=9858980 |
|
|
|
Post by Hot Christian Stocks on Mar 17, 2014 9:39:10 GMT -5
|
|
|
|
Post by Hot Christian Stocks on Mar 18, 2014 6:32:35 GMT -5
$NVLX presentation entitled "Cell-in-a-Box® Living Cell Encapsulation Products for Medical and Healthcare Use" given during the Clinical Trials section of the Convention's program, Dr. Günzburg reviewed the data from the early/mid-phase clinical trials that were done with the combination of Cell-in-a-Box® and the anti-cancer prodrug ifosfamide in patients with advanced inoperable pancreatic cancer; In those Phase 1 and Phase 2 clinical trials, the Cell-in-a-Box®/ifosfamide combination treatment was shown to essentially double the median survival time and percentage of one-year survivors over those seen in historical data for Gemzar® (gemcitabine), the only drug approved to date by the FDA as a single agent for the treatment of the disease. But unlike Gemzar®, Nuvilex's treatment had no serious treatment-related side effects associated with it because the dose of ifosfamide used in these trials was only one-third of that normally employed for cancer treatment. www.stockwatch.com/News/Item.aspx?bid=U-z10072790-U%3aNVLX-20140317&symbol=NVLX®ion=U |
|
|
|
Post by Hot Christian Stocks on Mar 19, 2014 8:31:32 GMT -5
|
|
|
|
Post by Hot Christian Stocks on Mar 20, 2014 8:06:34 GMT -5
$NVLX Contracts With Austrianova for cGMP-Compliant Cell-in-a-Box(R) Encapsulation of Cells for Clinical Trials NEW YORK, NY -- (Marketwired) -- 03/20/14 LiveDeal, Inc. (NASDAQ: LIVE) has generated a lot of attention since entering the online deal space and that attention has been well deserved. The company's instant, real-time concept makes more sense for users than the model used by long-time industry leaders like Groupon and others. Quite simply when business owners need more customers, they will create a promotion with an online deal site to help introduce their brand to potential consumers. LiveDeal launched its online deal platform in the restaurant industry, and with it, it's giving those restaurants the opportunity to reach customers immediately and in real-time. The introduction of this instant, real-time model gives www.livedeal.com plenty of potential as an on-going technology platform into the future. LiveDeal recently announced that it is ramping up its deal procurement team so that it can quickly grab market share. It is clear that the first step the company is taking is to build an audience. In technology, the name of the game is potential. Instagram, for instance, had 30 million users when it was acquired, but to arrive at a fair value for acquisition, the technology's future potential had to be included in the evaluation. Instagram has proven that potential with close to 150 million users. In technology, since most platforms are so scalable, those looking to acquire these technologies project 2, 3 and 5-years out in time to see where the product could be, and usually pay a multiple based on future potential, not actual results at the time. This bodes well for LiveDeal and its online and mobile deal engine, livedeal.com. LiveDeal seems to understand that the name of the game is potential and that building a technology's popularity by increasing its number of users could equate to more and more dollars in the company's future. With each major city that the company has added to its platform, there is the market to add thousands of new restaurants to create promotions and potentially millions of new consumers to view and use those real-time deals. Because LiveDeal's platform gives the restaurant owner all of the control, creates a direct relationship between merchant and consumer and eliminates the middleman by letting consumers pay for the promotions found on livedeal.com directly to the restaurant, the platform has to be taken seriously in the industry. Other online deal sites in the industry don't offer all of these advantages, so using a media campaign to drive more and more users to the company's platform should only serve to make this model the way merchants advertise promotions and consumers find their deals well into the future. www.stockwatch.com/News/Item.aspx?bid=U-z10073394-U%3aNVLX-20140320&symbol=NVLX®ion=U |
|
|
|
Post by Kimmy Jay on Mar 25, 2014 8:57:18 GMT -5
 Penny Stock DivasProviding coverage of : Nuvilex, OTCQB: (NVLX) Nuvilex to Present at National Medical Cannabis Unity Conference in Washington DC SILVER SPRING, Md., March 25, 2014 (GLOBE NEWSWIRE) -- Nuvilex, Inc. (OTCQB:NVLX), a clinical-stage international biotechnology company providing cell and gene therapy solutions for the treatment of diseases, announced today that holistic and medical marijuana expert Dr. Mark L. Rabe, Chairman of the Scientific Advisory Board of Nuvilex's subsidiary, Medical Marijuana Sciences, Inc., will deliver a significant presentation at the 2nd Annual National Medical Cannabis Unity Conference "Navigating Medical Cannabis in the Mainstream" that will be held in Washington, DC April 5-7, 2014. Dr. Rabe's presentation will take place at the Mayflower Hotel on April 6. Dr. Rabe will review the history of the use of marijuana and its constituents for medicinal purposes and discuss the constituents of the marijuana plant, known as cannabinoids, which have historically shown biological activity, with particular emphasis on their use in treating serious and deadly diseases. Most importantly, Dr. Rabe will speak to the potential use of cannabinoids in combination with the proprietary cellulose-based live cell encapsulation technology known as Cell-in-a-Box® in developing treatments for pancreatic and brain cancer, two of the deadliest forms of that disease. Cell-in-a-Box®, in combination with the anticancer drug ifosfamide, was proven effective in early-stage clinical trials and is currently being prepared for late-stage clinical trials by Nuvilex for the treatment of advanced, inoperable pancreatic cancer. The National Medical Cannabis Unity Conference is sponsored by Americans for Safe Access (ASA). The goals of the ASA are to ensure safe and legal access to marijuana (cannabis) for therapeutic uses and research. The Conference will allow patients, medical practitioners and advocates of medical marijuana to interact, exchange ideas and discuss the navigation of medical marijuana in today's political landscape. Kenneth L. Waggoner, CEO and President of Nuvilex, commented, "The presentation by Dr. Rabe at this important conference will help showcase Medical Marijuana Sciences and its efforts to develop cannabis-based cancer treatments to a diverse community of those with a genuine interest in developing constituents of marijuana for medical treatment of serious diseases and their associated symptoms. It is our hope that, through events such as the National Medical Cannabis Unity Conference, the usefulness of constituents of cannabis for serious and deadly diseases can ultimately be fully realized."
|
|
|
|
Post by Hot Christian Stocks on Apr 1, 2014 8:06:25 GMT -5
|
|
|
|
Post by Hot Christian Stocks on Apr 2, 2014 7:53:55 GMT -5
|
|
|
|
Post by Hot Christian Stocks on Apr 3, 2014 8:05:35 GMT -5
|
|
|
|
Post by Hot Christian Stocks on Apr 7, 2014 8:27:22 GMT -5
|
|
|
|
Post by Hot Christian Stocks on Apr 8, 2014 8:16:35 GMT -5
$NVLX - Medical Marijuana Sciences' Dr. Mark L. Rabe Speaks at ASA Medical Cannabis Unity Conference in Washington DC SILVER SPRING, Md., April 8, 2014 (GLOBE NEWSWIRE) -- Medical Marijuana Sciences, Inc., a subsidiary of Nuvilex, Inc. (OTCQB:NVLX), a clinical-stage international biotechnology company providing cell and gene therapy solutions for the treatment of diseases, reported today that Dr. Mark L. Rabe's presentation at the National Medical Cannabis Unity Conference, held this past weekend in Washington DC, prompted numerous questions and a lively discussion on Nuvilex's proprietary Cell-in-a-Box® platform and how Medical Marijuana Sciences is working to combine it with the cancer-fighting properties of cannabinoids. The conference, hosted by Americans for Safe Access (ASA) and titled, "Navigating Medicinal Cannabis in the Mainstream," was attended by several hundred medical marijuana patients, parents of pediatric patients, educators, veterans, physicians, and other individuals calling for a stronger commitment to the safe, medicinal use of cannabis. "It was a profound and humbling experience to see the dedication, commitment and sacrifice put forth by the members and sponsors of the ASA. This group of individuals has fought tirelessly to provide patients with safe access to cannabis-based medicine," said Dr. Rabe. "It was also encouraging to hear recently from the federal government comments about the potential of reclassifying or declassifying cannabis from its present status, which would provide the opportunity to advance scientific research and further the development of potentially life-saving cannabinoid-based therapies." Dr. Rabe's presentation, "Targeted Cannabinoid-based Chemotherapy Utilizing Cell-in-a-Box® Technology," addressed new research that Medical Marijuana Sciences is undertaking in the fight against pancreatic and brain cancers and highlighted how further research is needed to help prevent the tens of thousands of deaths that occur each year as a result of these two diseases. "Dr. Rabe is Chairman of Medical Marijuana Sciences' Scientific Advisory Board and is a well-respected veteran in the discussion of medical marijuana. His insight on the potential use of cannabinoids, particularly in combination with our parent company's Cell-in-a-Box® technology to treat these difficult cancers, has proven vital to our evolution as a company," said Tim Matula, President of Medical Marijuana Sciences. "Recent surveys have demonstrated that oncologists, among other top medical practitioners, have a keen interest in the potential use of cannabinoids both in compassionate care and in the fight against cancer and other deadly diseases; many have spoken and continue to speak openly about its decriminalization and the possible research applications that could result." About Medical Marijuana Sciences: Medical Marijuana Sciences, Inc. is the newest wholly-owned subsidiary of Nuvilex, Inc. It was established in early 2013 with the initial mission to develop treatments based on constituents of cannabis for two of the most serious and deadly forms of cancer, namely brain and pancreatic cancers. www.stockwatch.com/News/Item.aspx?bid=U-i1104909-U%3aLIVE-20140408&symbol=LIVE®ion=U |
|
